MeSH tree: D12.776.377.715.548.114.224
Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells, using a strategy that could make cancer immunotherapy work for many more patients.
Dec 16, 2025
0
47
Children with a rare form of cancer called neuroblastoma which hasn't responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to new results from a clinical ...
Dec 12, 2025
0
0
Antibody treatments for cancer and other diseases are typically delivered intravenously, because of the large volumes that are needed per dose. This means the patient has to go to a hospital for every treatment, where they ...
Dec 11, 2025
0
14
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending ...
Dec 10, 2025
0
0
Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E antibodies in humanized mice, protects against Immunoglobulin E-mediated anaphylaxis, and shows no detectable ...
A new international study published in Osteoporosis International and led by Monash's Center for Medicine Use and Safety (CMUS) has investigated the risks of a second hip fracture, subsequent fractures, and death in people ...
Dec 8, 2025
0
0
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal ...
Dec 7, 2025
0
39
The American Gastroenterological Association (AGA) has released a comprehensively updated clinical guideline on the pharmacological management of moderate-to-severe Crohn's disease. The new guideline uses cutting-edge network ...
Nov 20, 2025
0
3
A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of treatment.
Nov 18, 2025
0
0
Early data from a Phase 2 clinical trial show a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.
Nov 7, 2025
0
0
